Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors

Xenon Pharmaceuticals Inc.

Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.
Justin Gover was founding CEO of GW Pharma (sold for $7.2B) and led development of Epidiolex for epilepsy.
Appointments effective August 8, 2023; both will receive standard non-employee director compensation.
Their expertise aligns with Xenon's advancing XEN1101 in Phase 3 epilepsy trials and Phase 2 MDD study.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mr. Justin Gover

director

XENE · Xenon Pharmaceuticals Inc.

Effective: 2023-08-08
Filed: August 8, 2023, 7:59 PM ET

appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.

Appointed

Dr. Gillian Cannon

director

XENE · Xenon Pharmaceuticals Inc.

Effective: 2023-08-08
Filed: August 8, 2023, 7:59 PM ET

appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mr. Justin Gover was appointed as director at Xenon Pharmaceuticals Inc..

Action: appointed
Role: director

Exact text from the filing

appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Gillian Cannon was appointed as director at Xenon Pharmaceuticals Inc..

Action: appointed
Role: director

Exact text from the filing

appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.

View on SEC.gov

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.